PHILADELPHIA, PA / ACCESS Newswire / September 29, 2025 / Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of MoonLake Immunotherapeutics ("MoonLake") (NASDAQ:MLTX).
The investigation concerns MoonLake’s report of "week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab." Among other things, MoonLake stated "[t]he higher-than-expected placebo response rate in VELA-2 is disappointing . . .."
On the news of disappointing Phase 3 VELA results, MoonLake’s stock price dropped significantly and was down more than 89% during intraday trading on September 29, 2025.
MoonLake investors are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, myarnoff@kehoelawfirm.com, info@kehoelawfirm.com, to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.
ABOUT KEHOE LAW FIRM, P.C.
Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.
Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.
This press release may constitute attorney advertising.
SOURCE: Kehoe Law Firm, P.C.
View the original press release on ACCESS Newswire
COMTEX_469151434/2457/2025-09-29T13:45:23